<DOC>
	<DOCNO>NCT00519636</DOCNO>
	<brief_summary>The purpose replicate study FFU105924 provide data subject preference FFNS compare FPNS .</brief_summary>
	<brief_title>Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS</brief_title>
	<detailed_description>A Randomized , Double-Blind , Placebo-Controlled , Active Comparator , One-Week , Cross-Over , Multicenter Study Evaluate Efficacy , Patient Preference Experience One-Daily , Intranasal Administration 110mcg Fluticasone Furoate Nasal Spray 200mcg Fluticasone Propionate Nasal Spray Adult Subjects Seasonal Allergic Rhinitis ( FFU105927 )</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Informed consent Subject provide appropriately sign date informed consent . Otherwise healthy outpatient fall allergy Subject treatable outpatient basis . Age 18 year age old time Visit 2 Male eligible female Female subject enrol plan become pregnant time study participation . A urine pregnancy test require female visit determine subject pregnant . To eligible entry study , female childbearing potential must commit consistent correct use acceptable method birth control , define follow : Abstinence Females childbearing potential sexually active must commit complete abstinence intercourse two week exposure study drug , throughout clinical trial , period trial account elimination drug ( minimum six day ) . Oral contraceptive ( either combine estrogen/progestin progestin ) Injectable progestogen Implants levonorgestrel Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 % per year , Male partner sterile ( vasectomy documentation azoospermia ) prior female subject 's entry study sole sexual partner female subject Double barrier methodcondom occlusive cap ( diaphragm cervical /vault cap ) plus spermicide Estrogenic vaginal ring Diagnosis SAR SAR define follow : A clinical history ( write verbal ) SAR seasonal allergy symptom ( nasal symptom ) last two fall allergy season , A positive skin test ( prick method ) fall allergen prevalent geographic area conduct study , within 12 month prior Visit 1 Visit 1 . A positive skin test define wheal 3 mm large diluent control prick testing . In vitro test specific IgE ( RAST , PRIST ) allow diagnosis SAR . Subjects meet criterion may also perennial allergic rhinitis vasomotor rhinitis eligible randomization . Adequate exposure seasonal pollen Subject reside within geographical region exposure fall seasonal allergen expect significant entire study period . Subject plan travel outside area 48 hour study period . Ability comply study procedure Subject understand willing , able likely comply study procedure restriction . Literate Subject must able read , comprehend , record information English . Recent use ( less 1 year ) use brand ( FLONASE ) generic FPNS use FFNS ( VERAMYST ) . Significant concomitant medical condition , define limited : A historical current evidence clinically significant uncontrolled disease body system ( e.g. , tuberculosis , psychological disorder , eczema ) . Significant defined disease , opinion investigator , would put safety subject risk study participation would confound interpretation study result disease/condition exacerbate study . A severe physical obstruction nose ( e.g. , deviated septum nasal polyp ) nasal septal perforation could affect deposition intranasal study drug Nasal ( eg , nasal septum ) injury surgery last 3 month Asthma , exception mild intermittent asthma [ National Asthma Education Prevention Program ( NARPP ) Guidelines , 2002 ] . Rhinitis medicamentosa Bacterial viral infection ( e.g. , common cold ) eye upper respiratory tract within two week Visit 1 screening period Documented evidence acute significant chronic sinusitis , determine individual investigator Current history glaucoma and/or cataract ocular herpes simplex Physical impairment would affect subject 's ability participate safely fully study Clinical evidence Candida infection nose History psychiatric disease , intellectual deficiency , poor motivation , substance abuse ( include drug alcohol ) condition limit validity inform consent would confound interpretation study result History adrenal insufficiency History shingle Chickenpox measles : A subject eligible he/she currently chickenpox measles , expose chickenpox measles last 3 week nonimmune . If subject develop chickenpox measles study , he/she withdrawn study . If nonimmune subject expose chickenpox measles study , his/her continuation study discretion investigator , take consideration likelihood develop active disease . Use corticosteroid , define : Intranasal corticosteroid within four week prior Visit 1 . Inhaled , oral , intramuscular , intravenous , ocular , and/or dermatological corticosteroid ( exception hydrocortisone cream/ointment , 1 % less ) within eight week prior Visit 1 . Use allergy medication within timeframe indicated relative Visit 1 Intranasal cromolyn within 14 day prior Visit 1 Shortacting prescription OTC antihistamine , include antihistamine contain insomnia 'nighttime ' pain formulation take insomnia , within 3 day prior Visit 1 Longacting antihistamine within 10 day prior Visit 1 : loratadine , desloratadine , fexofenadine , cetirizine Oral intranasal decongestant within 3 day prior Visit 1 Intranasal , oral , inhaled anticholinergic within 3 day prior Visit 1 Oral antileukotrienes within 3 day prior Visit 1 Subcutaneous omalizumab ( Xolair ) within 5 month Visit 1 Intranasal antihistamine ( e.g . Astelin ) within 2 week prior Visit 1 Use medication may affect allergic rhinitis symptom Chronic use concomitant medication , tricyclic antidepressant , would affect assessment effectiveness study drug Chronic use longacting betaagonists ( e.g. , salmeterol ) Chronic use intranasally administer medication ( e.g. , calcitoninsalmon ) Nasal irrigation solution Use immunosuppressive medication 8 week prior screen study Use medication significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 , include ritonavir ketoconazole Immunotherapy Subjects may enrol study immunotherapy initiate within 30 day Visit 1 , dose remain fixed 30 day prior Visit 1 , dose remain fixed duration study . Allergy/Intolerance Known hypersensitivity corticosteroid excipients product Clinical trial/experimental medication experience Has recent exposure investigational study drug within 30 day Visit 1 Participation previous current GSK FFNS study Positive inconclusive pregnancy test female breastfeeding Has positive inconclusive pregnancy test Visit 1 Visit 2 Affiliation investigational site Subject participate investigator , subinvestigator , study coordinator , employee participate investigator , immediate family member aforementioned . Current tobacco use Subject currently use smoking product include cigarette , cigar , pipe chew tobacco .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>experience</keyword>
	<keyword>GW685698X</keyword>
	<keyword>fluticasone furoate</keyword>
	<keyword>preference</keyword>
	<keyword>seasonal allergic rhinitis</keyword>
	<keyword>fluticasone propionate</keyword>
</DOC>